These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18221871)

  • 1. Pyrazinoindolone inhibitors of MAPKAP-K2.
    Goldberg DR; Choi Y; Cogan D; Corson M; DeLeon R; Gao A; Gruenbaum L; Hao MH; Joseph D; Kashem MA; Miller C; Moss N; Netherton MR; Pargellis CP; Pelletier J; Sellati R; Skow D; Torcellini C; Tseng YC; Wang J; Wasti R; Werneburg B; Wu JP; Xiong Z
    Bioorg Med Chem Lett; 2008 Feb; 18(3):938-41. PubMed ID: 18221871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and SAR studies of indole-based MK2 inhibitors.
    Xiong Z; Gao DA; Cogan DA; Goldberg DR; Hao MH; Moss N; Pack E; Pargellis C; Skow D; Trieselmann T; Werneburg B; White A
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1994-9. PubMed ID: 18291646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of carboline analogs as potent MAPKAP-K2 inhibitors.
    Wu JP; Wang J; Abeywardane A; Andersen D; Emmanuel M; Gautschi E; Goldberg DR; Kashem MA; Lukas S; Mao W; Martin L; Morwick T; Moss N; Pargellis C; Patel UR; Patnaude L; Peet GW; Skow D; Snow RJ; Ward Y; Werneburg B; White A
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4664-9. PubMed ID: 17576063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meroterpenoid MAPKAP (MK2) inhibitors isolated from the indonesian marine sponge Acanthodendrilla sp.
    Williams DE; Telliez JB; Liu J; Tahir A; van Soest R; Andersen RJ
    J Nat Prod; 2004 Dec; 67(12):2127-9. PubMed ID: 15620270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach.
    Kosugi T; Mitchell DR; Fujino A; Imai M; Kambe M; Kobayashi S; Makino H; Matsueda Y; Oue Y; Komatsu K; Imaizumi K; Sakai Y; Sugiura S; Takenouchi O; Unoki G; Yamakoshi Y; Cunliffe V; Frearson J; Gordon R; Harris CJ; Kalloo-Hosein H; Le J; Patel G; Simpson DJ; Sherborne B; Thomas PS; Suzuki N; Takimoto-Kamimura M; Kataoka K
    J Med Chem; 2012 Aug; 55(15):6700-15. PubMed ID: 22746295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors.
    Rao AU; Xiao D; Huang X; Zhou W; Fossetta J; Lundell D; Tian F; Trivedi P; Aslanian R; Palani A
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1068-72. PubMed ID: 22182499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent.
    Curran KJ; Verheijen JC; Kaplan J; Richard DJ; Toral-Barza L; Hollander I; Lucas J; Ayral-Kaloustian S; Yu K; Zask A
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1440-4. PubMed ID: 20089401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.
    Schlapbach A; Feifel R; Hawtin S; Heng R; Koch G; Moebitz H; Revesz L; Scheufler C; Velcicky J; Waelchli R; Huppertz C
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6142-6. PubMed ID: 18945615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800.
    Fujino A; Fukushima K; Namiki N; Kosugi T; Takimoto-Kamimura M
    Acta Crystallogr D Biol Crystallogr; 2010 Jan; 66(Pt 1):80-7. PubMed ID: 20057052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
    Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P
    Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies.
    Miglani R; Cliffe IA; Voleti SR
    Eur J Med Chem; 2010 Jan; 45(1):98-105. PubMed ID: 19850376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of a series of multi-isoform PI3 kinase inhibitors.
    Perry B; Beevers R; Bennett G; Buckley G; Crabbe T; Gowers L; James L; Jenkins K; Lock C; Sabin V; Wright S
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5299-302. PubMed ID: 18774713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrazole-based cathepsin S inhibitors with improved cellular potency.
    Wei J; Pio BA; Cai H; Meduna SP; Sun S; Gu Y; Jiang W; Thurmond RL; Karlsson L; Edwards JP
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5525-8. PubMed ID: 17822900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural analysis of carboline derivatives as inhibitors of MAPKAP K2 using 3D QSAR and docking studies.
    Nayana RS; Bommisetty SK; Singh K; Bairy SK; Nunna S; Pramod A; Muttineni R
    J Chem Inf Model; 2009 Jan; 49(1):53-67. PubMed ID: 19119997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
    Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
    J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy.
    Velcicky J; Feifel R; Hawtin S; Heng R; Huppertz C; Koch G; Kroemer M; Moebitz H; Revesz L; Scheufler C; Schlapbach A
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1293-7. PubMed ID: 20060294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors.
    Shafer CM; Lindvall M; Bellamacina C; Gesner TG; Yabannavar A; Jia W; Lin S; Walter A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4482-5. PubMed ID: 18672368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of ring-fused pyrazolo pyridin-2-ones as novel poly(ADP-ribose)polymerase-1 inhibitors.
    Moree WJ; Goldman P; Demaggio AJ; Christenson E; Herendeen D; Eksterowicz J; Kesicki EA; McElligott DL; Beaton G
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5126-9. PubMed ID: 18713665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.
    Revesz L; Schlapbach A; Aichholz R; Dawson J; Feifel R; Hawtin S; Littlewood-Evans A; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4719-23. PubMed ID: 20591669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.